Millennium begins Phase II

MLNM began a Phase II trial of LDP-977 oral 5-lipoxygenase inhibitor to treat asthma. The double-blind, placebo-controlled trial will study the safety and efficacy of LDP-977 in 320 patients. LDP-977 ...